Delcath Systems
NEW YORK, NY, United States · Biotechnology, Health Care · 86 employees
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Funding history
- Series series e — $16.3M — Dec 2024
- Funding Round — $7.0M — Mar 2024
- Funding Round — $35.0M — Sep 2023
- Funding Round — $25.0M — Mar 2023
- Series seed — $3.8M — Dec 2022
Recent signals
- Nov 19, 2025: SEC 8-K (8.01): On November 19, 2025, Delcath Systems, Inc. authorized a share repurchase program allowing the company to repurchase up to $25 million of its outstanding shares of common stock. This initiative is subject to market conditions, indicating a strategic move to enhance shareholder value and manage capital effectively. The decision reflects the board's confidence in the company's financial health and future prospects.
- Dec 30, 2024: Raised $16.3M in Series series e
- Mar 26, 2024: Raised $7.0M
- Mar 18, 2024: Delcath Appoints Martha S. Rook as Chief Operating Officer
- Sep 01, 2023: Raised $35.0M
- Jun 20, 2023: Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer
- Jun 07, 2023: Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance
- Mar 31, 2023: Raised $25.0M
See plans & pricing → Track Delcath Systems’s funding, hiring, and signals — with verified contacts — on Fundz.